← RAPT Therapeutics, Inc. (RAPT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RAPT Therapeutics, Inc. (RAPT)
Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
RAPT Therapeutics (RAPT) is a ~60-person clinical-stage pharmaceutical company with a market cap of approximately $1.6B and two Phase 2 assets: FLX475 in advanced cancer and RPT904 in IgE-mediated food allergy. The company has no revenue to speak of (negligible in recent years) and has been burning roughly $100–130M annually in R&D, with net losses accelerating from $53M in 2020 to $130M in 2024. Financial details including cash runway, dilution history, and short interest are not disclosed in available data.
The catalyst path
- 2027-04-15 (est.)Phase 2 · RPT904imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FLX475 | Phase 2 | Advanced Cancer |
| RPT904 | Phase 2 | Ig-E Mediated Food Allergy |
Price & technical context
3-month
+74.4%
6-month
+406.3%
12-month
+565.4%
52-wk range
$5.98–$58.02
vs 50-day MA
+21.8%
vs 200-day MA
+126.8%
Realized vol
109.7%
Max drawdown
-97.2%
Daily closes through 2026-03-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RAPT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.